Medication info
Rosutero Tablet 10mg (Rosuvastatin Calcium)

Rosutero Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201005762 · Approved 2010.09.29 · Insurance code 646003490

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL-cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more based on LDL-cholesterol levels, the treatment goal, and the patient's response; the dose may be increased up to a maximum of 20 milligrams per day. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
Child dose
Age 10 years ~ age 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is primarily used as an adjunct to dietary therapy in patients with primary hypercholesterolemia and mixed dyslipidemia. It also helps lower cholesterol levels when administered in conjunction with other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. It slows the progression of atherosclerosis by controlling total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia within target ranges. It may also be used in pediatric patients with familial hypercholesterolemia not controlled by diet alone. It is suitable as an adjunct to diet in patients with primary dysbetalipoproteinemia. This medication reduces the risk of cardiovascular diseases, thereby decreasing the risk of stroke, myocardial infarction, and vascular intervention. Therefore, this medication is effectively used for the treatment and reduction of hypercholesterolemia and cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL-cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more based on LDL-cholesterol levels, the treatment goal, and the patient's response; the dose may be increased up to a maximum of 20 milligrams per day. 3. Elderly patients : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Child dose

Age 10 years ~ age 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patient populations. For example, individuals with allergies to any component of this medication, those with severe liver impairment, those with muscular disorders, and patients with severely diminished renal function should not be administered this drug. Women who are pregnant, nursing, or potentially pregnant should consult a physician and ensure appropriate contraceptive measures before using this medication. Caution is especially warranted with high doses as they pose a greater risk of muscle-related issues. This medication contains lactose, so patients with genetic metabolic disorders such as lactose intolerance should not take it. Patients with a history of liver disease or those who consume a large amount of alcohol should undergo regular liver function tests before starting and during treatment with this medication. Individuals with hypothyroidism or nephrotic syndrome should first treat those conditions before use. If symptoms such as myalgia, muscle weakness, or cramps occur, the physician should be notified immediately, and muscle-related tests should be performed during treatment with this medication. If an acute serious condition arises, this drug should be discontinued. If symptoms of severe muscle weakness or ophthalmoplegia occur, use should be stopped immediately. When using this medication concurrently with other drugs, caution regarding drug interactions is advised, especially with drugs that may increase the risk of muscle toxicity. Regular testing of liver and kidney functions is recommended during treatment with this medication. This medication should not be used during pregnancy or breastfeeding, and women planning to become pregnant must consult a physician. In the case of an overdose, there is no specific antidote, so treatment should be symptomatic, and liver function and muscle enzyme levels should be monitored. Caution is necessary when driving or operating machinery as dizziness may occur. Finally, this medication shows higher systemic exposure in Asians, so dose adjustments may be necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced erythema multiforme, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, forgetfulness, amnesia, memory disorders, confusion, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, sensory disturbances, chest discomfort, anorexia, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is important to maintain a temperature between 1 and 30 degrees Celsius when storing the medication to ensure its effectiveness is preserved safely.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.